HC Wainwright Cuts REGENXBIO (NASDAQ:RGNX) Price Target to $36.00

REGENXBIO (NASDAQ:RGNX) had its price objective decreased by HC Wainwright from $40.00 to $36.00 in a report released on Thursday,Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock.

A number of other research firms have also issued reports on RGNX. StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, September 20th. Raymond James restated an “outperform” rating and issued a $18.00 price objective on shares of REGENXBIO in a research note on Thursday, October 10th. Barclays cut their target price on shares of REGENXBIO from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. Morgan Stanley restated an “overweight” rating and issued a $22.00 price target on shares of REGENXBIO in a research report on Friday, November 15th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $52.00 price objective on shares of REGENXBIO in a research report on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $35.27.

REGENXBIO Stock Up 4.5 %

Shares of RGNX stock opened at $9.59 on Thursday. The business’s 50 day moving average is $10.24 and its two-hundred day moving average is $12.00. The company has a market cap of $475.09 million, a PE ratio of -1.91 and a beta of 1.23. REGENXBIO has a 12 month low of $8.53 and a 12 month high of $28.80.

Insider Activity

In other news, Director Argeris N. Karabelas sold 10,000 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total value of $101,100.00. Following the sale, the director now owns 11,286 shares in the company, valued at approximately $114,101.46. The trade was a 46.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 13.13% of the company’s stock.

Institutional Investors Weigh In On REGENXBIO

Hedge funds have recently made changes to their positions in the company. FMR LLC lifted its stake in shares of REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 1,656 shares during the period. nVerses Capital LLC raised its position in shares of REGENXBIO by 183.3% during the 3rd quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 2,200 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of REGENXBIO by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 3,720 shares during the period. Diversified Trust Co bought a new position in shares of REGENXBIO in the 2nd quarter worth $121,000. Finally, Arizona State Retirement System grew its stake in shares of REGENXBIO by 20.6% during the second quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company’s stock worth $137,000 after purchasing an additional 1,997 shares during the period. Institutional investors and hedge funds own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.